Preferences towards treatment attributes among patients with Crohn’s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experiment

Immunosuppressants and biologics are the mainstay of treatment in patients with inflammatory bowel disease (IBD). Understanding patient preferences informs treatment decision-making and may optimize treatment acceptance and adherence. There is a lack of evidence regarding preferences towards treatment attributes among patients with IBD from non-Western countries.

This study aims to describe the preferences of patients with Crohn’s disease (CD) and ulcerative colitis (UC) towards the attributes of treatment with advanced therapies for IBD, including safety and efficacy profiles, frequency and route of administration (RoA) in a real-world setting from 5 countries – Argentina, Australia, Brazil, Saudi Arabia and Taiwan.